The company has also started working with a large pharma company on the API supply of a recently launched animal and human health product
It is anticipated to be safe and efficacious by targeting the receptor-binding domain (RBD) of the new coronavirus
It is the first orally administered therapy for the treatment of two types of ANCA-associated vasculitis approved in Japan
Surufatinib is the third potential new medicine discovered by the company to enter into clinical development in Japan
Takeda is establishing the capability to manufacture TAK-019 (known outside Japan as NVX-CoV2373) at its facilities in Japan and aims to begin distribution in the early calendar year 2022
Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options
Approval based on pivotal KOMET Phase III trial demonstrating significant tumour reduction in adults with NF1
Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions
The submissions are supported by data from the Phase 3 KEYNOTE-905 trial
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
Subscribe To Our Newsletter & Stay Updated
